Published in Cancer Weekly, August 5th, 2003
The appointment comes as Light Sciences has successfully completed phase I/II studies of its lead product, Litx, in advanced solid cancers.
Prior to founding Corus, Montgomery served as executive VP of research and development at PathoGenesis Corporation. Montgomery's accomplishments at PathoGenesis included the development and regulatory approval of inhaled tobramycin treatment for cystic fibrosis in the United States, Europe and other countries. In addition, Montgomery helped Genentech, Inc., develop Pulmozyme Inhalation...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.